Beneficiaries in these states, which include residents of New York, Illinois, and Ohio, can only access GLP-1s like Ozempic, Mounjaro, or Rybelsus if they have a Type 2 diabetes diagnosis
CKD: Use SGLT2 inhibitors or GLP-1 RA to slow CKD progression
A small, localized red spot is typically just part of the process
Its skin whitening properties help render glowing white skin
The conditions that most commonly support eligibility include: Obesity (BMI 30, or 27 with at least one comorbidity such as hypertension, sleep apnea, or cardiovascular disease) Type 2 diabetes or prediabetes Insulin resistance with clinical documentation Metabolic syndrome (clinically diagnosed) Polycystic Metabolic Ovarian Syndrome (PMOS) and related hormonal disorders Non-alcoholic fatty liver disease (NAFLD/MASLD) Perimenopause-related metabolic dysfunction with documented hormonal changes GLP-1 receptor agonists including semaglutide, tirzepatide, and retatrutide are the most commonly used peptides in metabolic care today
Mutations in the lipoyltransferase LIPT1 gene cause a fatal disease associated with a specific lipoylation defect of the 2-ketoacid dehydrogenase complexes
